Objectif Injuries and degenerative diseases of the central nervous system constitute a bottleneck in medical and surgical practice for which no therapy currently exists. To ensure clinical translation, NeuroGraft is organised in three R&D Work-Packages. NeuroGraft will develop functionalised cell seeded bioartificial organs, specifically spinal cord conduits for transplantation, incorporating a potent immunomodulatory cytokine (IL37) to target the initial inflammatory response to increase the survival and therapeutic efficacy of transplanted mesenchymal cells and the expression of potent neuro-regulatory molecules for enhanced functional nerve regeneration in the central nervous system.This exciting concept will be realised through the NeuroGraft consortium, consisting of one academic and four industrial partners (all SMEs), across four countries, with distinct synergistic expertise (including regulatory expertise) to develop cell seeded functionalised bioartificial organs as valuable solutions towards spinal cord repair. Regulatory advice is incorporated at an early stage in the development cycle, to facilitate the translation of the novel bioartificial devices developed, to the market in as short a timeframe as possible. The NeuroGraft consortium will validate the safety, efficacy and biodistribution of the functionalised bioartificial organs developed in a pre-clinical model of spinal cord under GLP conditions. Full Quality Assurance reports will be completed towards CE Mark regulatory approval of the medical device for spinal cord repair. These studies will facilitate progression to clinical trials of the technology (post project) and the development of a marketable product within 6 years of the completion of the NeuroGraft project. Intellectual property will be patented ensuring that SME’s have veto rights on commercial route for exploitation. An extensive business plan outlining detailed valorisation plan is presented. Champ scientifique sciences naturellessciences biologiquesneurobiologiesciences médicales et de la santémédecine cliniquetransplantation Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2012.1.4-2 - Medical technology for transplantation and bioartificial organs Appel à propositions FP7-HEALTH-2012-INNOVATION-2 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur NATIONAL UNIVERSITY OF IRELAND GALWAY Adresse University road H91 Galway Irlande Voir sur la carte Région Ireland Northern and Western West Type d’activité Higher or Secondary Education Establishments Contact administratif Mari Vahey (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Contribution de l’UE € 1 347 138,24 Participants (4) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire ASHLAND SPECIALTIES IRELAND LIMITED Irlande Contribution de l’UE € 797 383,60 Adresse National science park, building v, dublin road, petitswood N91 F6PD Mullingar, westmeath Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Colm O'dowd (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SA Portugal Contribution de l’UE € 1 053 415,50 Adresse Parque de ciencia e tecnologia avepark zona industrial da gandra 4805-017 Barco gmr Voir sur la carte Région Continente Norte Ave Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Celia Pinto (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window NAMSA France Contribution de l’UE € 513 550,00 Adresse Chemin de l islon 115 38670 Chasse sur rhone Voir sur la carte Région Auvergne-Rhône-Alpes Rhône-Alpes Isère Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Eleonore Puissant (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window OBELIS SA Belgique Contribution de l’UE € 499 887,50 Adresse Boulevard general wahis 53 1030 Bruxelles / brussel Voir sur la carte Région Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Doram Elkayam (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window
